Last month, the newly created Lustgarten Foundation for Pancreatic Cancer Research sponsored a meeting in collaboration with Cold Spring Harbor Laboratory that brought together a diverse group of basic and clinical scientists to discuss new developments in pancreatic cancer research. The foundation was established in 1999 in honor of Marc Lustgarten, the former vicechairman of Cablevision, who died of pancreatic cancer last year. Scientific leaders presented exciting work on animal models of cancer, signal transduction pathways, genetic alterations in cancer and receptor tyrosine kinase inhibitors as new therapeutic agents.
In spite of the high quality of talks, there was a relative paucity of solutions as to how to better diagnose, treat and prevent pancreatic cancer. It is admirable that the Lustgarten Foundation has recognized the need to bring researchers together to share ideas and begin to address issues. The meeting served as an excellent example of how basic scientists, clinical scientists and clinicians need to work together to apply the tremendous advances in biomedical sciences to the treatment of human disease. Yet, in recent years, there has been growing concern over the numbers of physicians engaged in research (physician-scientists) and of medical students interested in academic research careers.
These concerns have become a top priority for the Federation of American Societies for Experimental Biology (FASEB). FASEB outlined the problems in a report published in February: "The overall pattern is clear and consistent: whereas biomedical research has been expanding over the last two decades, the physician-scientist workforce has not kept pace." The problem appears to stem from medical school training that poses increasing debt and increased time in preparation for a research career. The Medical Scientist Training Program (MSTP) of the National Institutes of Health (NIH) attracts students before entering medical school for research careers and has a good track record for preparing graduates to enter academic research. Yet most MSTP graduates perform basic or disease-oriented research. "We need to have a more expansive view of what areas are valid for research and to maximize the integration of medicine and research," says Burt Shapiro, director of the MSTP program.
But MSTP graduates make up only 2% of US medical school graduates. Other programs need to encourage students and graduates who decide to become researchers later on. "Those late bloomers are the pool we're most concerned about," says Timothy J. Ley, an author of the FASEB report. Among its recommendations, FASEB proposed a national program for medical school debt forgiveness for physicians who pursue research careers. An outline of the proposal will be given to the NIH and, if approved, will need legislation from Congress. The intramural program of the NIH already supports four debt repayment programs and has endorsed the institution of similar extramural programs.
The NIH commissioned a panel of experts five years ago to study the waning interest in research by physicians and to recommend policy changes. The NIH responded to the panel's recommendations in several ways: special emphasis panels were created to focus on clinical research applications; clinical research curriculum (K30) awards were established to create clinical training courses; funding programs were created for new (K23) and midcareer (K24) investigators conducting patient-oriented research; the intramural clinical research training program was launched to train medical and dental students in clinical research; and the budgets for General Clinical Research Centers and for clinical trials were expanded considerably. The panel is now in the process of reviewing the early results of these programs.
Private foundations, including the Howard Hughes Medical Institute (HHMI), the Burroughs Wellcome Fund and the Doris Duke Charitable Foundation, as well as pharmaceutical companies, have made strong commitments to supporting physician-scientists. HHMI offers medical student and postdoctoral physician research fellowships. Monitoring of these programs is essential. "Self-reporting of graduates tells us that these fellowships have helped to solidify their interests in research, and over half of our graduates are conducting research," says Lou Simkowitz, HHMI's senior program officer for science education.
Although the NIH and foundation initiatives are a step in the right direction, success depends upon the ability of academic institutions to support the efforts of their physician-scientists. Greater cooperation among faculty of different disciplines is essential. The Dana Farber Cancer Institute has begun a collaboration with Harvard Medical School and its affiliates to bring all of the 780 members of the basic and clinical sciences together. "We have created disease programs and basic and populationbased scientific programs. Basic scientists are forced to break bread with clinicians and population biologists," explains David G. Nathan, president of the DanaFarber/Harvard Cancer Center.
In the near future, multidisciplinary, collaborative efforts among basic and clinical scientists, population scientists and clinicians will become even more crucial to apply the wealth of knowledge from the post-genome era to the improved diagnosis, treatment and prevention of disease. Continued analysis of the measures being taken by the NIH, private foundations, the pharmaceutical industry and academic medical centers is essential to success. We need to ensure that physicians are equipped with the tools necessary to allow patients to benefit from these efforts.
